{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T06:34:31Z","timestamp":1792132471733,"version":"4.4.0"},"reference-count":39,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2021,3,17]],"date-time":"2021-03-17T00:00:00Z","timestamp":1615939200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["OPPGH5342"],"award-info":[{"award-number":["OPPGH5342"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,9,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Bancroftian filariasis remains endemic in Fiji despite &amp;gt;10 years of mass drug administration (MDA) using diethylcarbamazine and albendazole (DA). The addition of ivermectin to this combination (IDA) has improved efficacy of microfilarial clearance at 12 months in individually randomized trials in nocturnal transmission settings, but impact in a setting of diurnally subperiodic filarial transmission has not been evaluated.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This cluster randomized study compared the individual efficacy and community impact of IDA vs DA as MDA for lymphatic filariasis in 35 villages on 2 islands of Fiji. Participants were tested at enrollment for circulating filarial antigen and, if positive, for microfilariae. Weight-dosed treatment was offered according to village randomization. Communities were visited at 12 months and retested for lymphatic filariasis. Infected individuals from Rotuma were retested at 24 months.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A total of 3816 participants were enrolled and 3616 were treated. At 12 months, microfilariae clearance was achieved in 72 of 111 participants detected with infection at baseline, with no difference in efficacy between treatment groups: DA, 69.2% (95% confidence interval [CI], 57.2%\u201379.1%) vs IDA, 62.5% (95% CI, 43.6%\u201378.2%); risk difference, 11.3 % (95% CI, \u201310% to 32.7%); P = .30. There was no difference between treatment groups in community prevalence of microfilariae at 12 months or individual clearance at 24 months.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>We found no difference between IDA and DA in individual clearance or community prevalence of lymphatic filariasis at 12 months, and no improved efficacy following a second annual round of IDA. Possible explanations for the apparent lack of benefit of IDA compared to DA include drug and parasite factors affecting clearance, and higher than expected reinfection rates.<\/jats:p>\n                  <jats:p>Clinical Trials Registration: NCT03177993 and Australian New Zealand Clinical Trial Registry: N12617000738325.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/cid\/ciab202","type":"journal-article","created":{"date-parts":[[2021,3,15]],"date-time":"2021-03-15T12:13:36Z","timestamp":1615810416000},"page":"994-1002","source":"Crossref","is-referenced-by-count":18,"title":["Individual Efficacy and Community Impact of Ivermectin, Diethylcarbamazine, and Albendazole Mass Drug Administration for Lymphatic Filariasis Control in Fiji: A Cluster Randomized Trial"],"prefix":"10.1093","volume":"73","author":[{"given":"Myra","family":"Hardy","sequence":"first","affiliation":[{"name":"Tropical Diseases Research Group, Murdoch Children\u2019s Research Institute, Melbourne, Victoria, Australia"},{"name":"Department of Paediatrics, University of Melbourne, ,Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josaia","family":"Samuela","sequence":"additional","affiliation":[{"name":"Fiji Ministry of Health and Medical Services, Suva, Fiji"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mike","family":"Kama","sequence":"additional","affiliation":[{"name":"Fiji Ministry of Health and Medical Services, Suva, Fiji"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meciusela","family":"Tuicakau","sequence":"additional","affiliation":[{"name":"Fiji Ministry of Health and Medical Services, Suva, Fiji"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Romani","sequence":"additional","affiliation":[{"name":"Kirby Institute, University of New South Wales, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margot J","family":"Whitfeld","sequence":"additional","affiliation":[{"name":"St Vincent\u2019s Hospital, University of New South Wales, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher L","family":"King","sequence":"additional","affiliation":[{"name":"Centre for Global Health and Diseases, Case Western Reserve University, Cleveland, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary J","family":"Weil","sequence":"additional","affiliation":[{"name":"Department of Medicine, Washington University, St Louis, Missouri, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anneke C","family":"Grobler","sequence":"additional","affiliation":[{"name":"Department of Paediatrics, University of Melbourne, ,Melbourne, Victoria, Australia"},{"name":"Clinical Epidemiology and Biostatistics Unit, Murdoch Children\u2019s Research Institute, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leanne J","family":"Robinson","sequence":"additional","affiliation":[{"name":"Vector-borne Diseases and Tropical Public Health, Burnet Institute, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John M","family":"Kaldor","sequence":"additional","affiliation":[{"name":"Kirby Institute, University of New South Wales, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew C","family":"Steer","sequence":"additional","affiliation":[{"name":"Tropical Diseases Research Group, Murdoch Children\u2019s Research Institute, Melbourne, Victoria, Australia"},{"name":"Department of Paediatrics, University of Melbourne, ,Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,3,17]]},"reference":[{"key":"2021091515523890900_CIT0001","first-page":"509","article-title":"Global programme to eliminate lymphatic filariasis: progress report, 2019","volume":"95","author":"World Health Organization","year":"2020","journal-title":"Wkly Epidemiol Rec"},{"key":"2021091515523890900_CIT0002","author":"World Health Organization","year":"2006"},{"key":"2021091515523890900_CIT0003","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1056\/NEJMoa1706854","article-title":"A trial of a triple-drug treatment for lymphatic filariasis","volume":"379","author":"King","year":"2018","journal-title":"N Engl J Med"},{"key":"2021091515523890900_CIT0004","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/S0035-9203(01)90257-3","article-title":"Long-term efficacy of single-dose combinations of albendazole, ivermectin and diethylcarbamazine for the treatment of bancroftian filariasis","volume":"95","author":"Ismail","year":"2001","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"2021091515523890900_CIT0005","doi-asserted-by":"crossref","first-page":"62","DOI":"10.4269\/ajtmh.2007.76.62","article-title":"Efficacy of single-dose diethylcarbamazine compared with diethylcarbamazine combined with albendazole against Wuchereria bancrofti infection in Papua New Guinea","volume":"76","author":"Bockarie","year":"2007","journal-title":"Am J Trop Med Hyg"},{"key":"2021091515523890900_CIT0006","doi-asserted-by":"crossref","first-page":"e344","DOI":"10.1371\/journal.pntd.0000344","article-title":"The impact of repeated rounds of mass drug administration with diethylcarbamazine plus albendazole on bancroftian filariasis in Papua New Guinea","volume":"2","author":"Weil","year":"2008","journal-title":"PLoS Negl Trop Dis"},{"key":"2021091515523890900_CIT0007","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S1473-3099(04)00973-9","article-title":"Mathematical modelling and the control of lymphatic filariasis","volume":"4","author":"Michael","year":"2004","journal-title":"Lancet Infect Dis"},{"key":"2021091515523890900_CIT0008","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1186\/s13071-015-1152-3","article-title":"Modelling strategies to break transmission of lymphatic filariasis\u2014aggregation, adherence and vector competence greatly alter elimination","volume":"8","author":"Irvine","year":"2015","journal-title":"Parasit Vectors"},{"key":"2021091515523890900_CIT0009","author":"World Health Organization","year":"2011"},{"key":"2021091515523890900_CIT0010","volume-title":"Rovings in the Pacific, from 1837 to 1849; with a glance at California by a merchant long resident at Tahiti","author":"Lucatt","year":"1851"},{"key":"2021091515523890900_CIT0011","author":"Nelson","year":"1956"},{"key":"2021091515523890900_CIT0012","volume-title":"Regional Office for the Western Pacific, South Pacific Commission. Report on the fourth joint WHO\/SPC seminar on filariasis and vector control: Apia, Western Samoa: 1 to 10 July 1974","author":"World Health Organization","year":"1974"},{"key":"2021091515523890900_CIT0013","first-page":"184","article-title":"Filariasis research in Fiji 1957\u20131959. Part II. Experiments in larval control of mosquito vectors","volume":"63","author":"Burnett","year":"1960","journal-title":"J Trop Med Hyg"},{"key":"2021091515523890900_CIT0014","first-page":"208","article-title":"Filariasis Research in Fiji 1957\u20131959. Part III. Experiments in control of adult mosquitoes","volume":"63","author":"Burnett","year":"1960","journal-title":"J Trop Med Hyg"},{"key":"2021091515523890900_CIT0015","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1093\/cid\/civ882","article-title":"Efficacy, safety, and pharmacokinetics of coadministered diethylcarbamazine, albendazole, and ivermectin for treatment of bancroftian filariasis","volume":"62","author":"Thomsen","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2021091515523890900_CIT0016","doi-asserted-by":"crossref","first-page":"e0007325","DOI":"10.1371\/journal.pntd.0007325","article-title":"Pharmacokinetics, safety, and efficacy of a single co-administered dose of diethylcarbamazine, albendazole and ivermectin in adults with and without Wuchereria bancrofti infection in C\u00f4te d\u2019Ivoire","volume":"13","author":"Edi","year":"2019","journal-title":"PLoS Negl Trop Dis"},{"key":"2021091515523890900_CIT0017","doi-asserted-by":"crossref","first-page":"e69","DOI":"10.1093\/cid\/ciz1050","article-title":"Efficacy and safety of a single dose of ivermectin, diethylcarbamazine and albendazole for treatment of lymphatic filariasis in C\u00f4te d\u2019Ivoire: an open-label, randomized, controlled trial","volume":"71","author":"Bjerum","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2021091515523890900_CIT0018","doi-asserted-by":"crossref","first-page":"e1002839","DOI":"10.1371\/journal.pmed.1002839","article-title":"The safety of double- and triple-drug community mass drug administration for lymphatic filariasis: a multicenter, open-label, cluster-randomized study","volume":"16","author":"Weil","year":"2019","journal-title":"PLoS Med"},{"key":"2021091515523890900_CIT0019","doi-asserted-by":"crossref","first-page":"e0008106","DOI":"10.1371\/journal.pntd.0008106","article-title":"The safety of combined triple drug therapy with ivermectin, diethylcarbamazine and albendazole in the neglected tropical diseases co-endemic setting of Fiji: a cluster randomised trial","volume":"14","author":"Hardy","year":"2020","journal-title":"PLoS Negl Trop Dis"},{"key":"2021091515523890900_CIT0020","doi-asserted-by":"crossref","first-page":"e0008298","DOI":"10.1371\/journal.pntd.0008298","article-title":"Safety and efficacy of co-administered diethylcarbamazine, albendazole and ivermectin during mass drug administration for lymphatic filariasis in Haiti: results from a two-armed, open-label, cluster-randomized, community study","volume":"14","author":"Dubray","year":"2020","journal-title":"PLoS Negl Trop Dis"},{"key":"2021091515523890900_CIT0021","author":"World Health Organization","year":"2017"},{"key":"2021091515523890900_CIT0022","article-title":"Community-level effectiveness of mass drug administration of ivermectin, diethylcarbamazine and albendazole versus diethylcarbamazine and albendazole for elimination of lymphatic filariasis in Papua New Guinea","volume":"101","author":"Laman","year":"2019","journal-title":"Am J Trop Med Hyg"},{"key":"2021091515523890900_CIT0023","first-page":"199","article-title":"Efficacy and effectiveness of a 3 drug regimen against a standard 2 drug regimen for lymphatic filariasis: results of an open-labelled cluster randomized trial","volume":"101","author":"Purushothaman","year":"2019","journal-title":"Am J Trop Med Hyg"},{"key":"2021091515523890900_CIT0024","volume-title":"Epidemiology of filariasis in the South Pacific","author":"Iyengar","year":"1965"},{"key":"2021091515523890900_CIT0025","first-page":"16","article-title":"Lymphatic filariasis in Fiji: incidence and review of literature","volume":"1","author":"National Health Research Office.","year":"2012","journal-title":"Fiji J Public Health"},{"key":"2021091515523890900_CIT0026","doi-asserted-by":"crossref","first-page":"11","DOI":"10.4269\/ajtmh.13-0089","article-title":"Laboratory and field evaluation of a new rapid test for detecting Wuchereria bancrofti antigen in human blood","volume":"89","author":"Weil","year":"2013","journal-title":"Am J Trop Med Hyg"},{"key":"2021091515523890900_CIT0027","first-page":"629","article-title":"Microfilaria survey methods and analysis of survey data in filariasis control programmes","volume":"37","author":"Sasa","year":"1967","journal-title":"Bull World Health Organ"},{"key":"2021091515523890900_CIT0028","doi-asserted-by":"crossref","first-page":"e0007541","DOI":"10.1371\/journal.pntd.0007541","article-title":"Dosing pole recommendations for lymphatic filariasis elimination: a height-weight quantile regression modeling approach","volume":"13","author":"Goss","year":"2019","journal-title":"PLoS Negl Trop Dis"},{"key":"2021091515523890900_CIT0029","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1111\/bcp.13840","article-title":"Population pharmacokinetics of oral ivermectin in venous plasma and dried blood spots in healthy volunteers","volume":"85","author":"Duthaler","year":"2019","journal-title":"Br J Clin Pharmacol"},{"key":"2021091515523890900_CIT0030","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.2165\/00003088-200342130-00001","article-title":"Dietary effects on drug metabolism and transport","volume":"42","author":"Harris","year":"2003","journal-title":"Clin Pharmacokinet"},{"key":"2021091515523890900_CIT0031","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1007\/s13238-018-0547-2","article-title":"Pharmacomicrobiomics: a novel route towards personalized medicine?","volume":"9","author":"Doestzada","year":"2018","journal-title":"Protein Cell"},{"key":"2021091515523890900_CIT0032","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/S0035-9203(97)90405-3","article-title":"Assessment of the efficacy of diethylcarbamazine on adult Wuchereria bancrofti in vivo","volume":"91","author":"Nor\u00f5es","year":"1997","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"2021091515523890900_CIT0033","author":"World Health Organization, Regional Office for the Western Pacific","year":"2006"},{"key":"2021091515523890900_CIT0034","doi-asserted-by":"crossref","first-page":"S143","DOI":"10.1179\/000349802125002509","article-title":"Limitation and facilitation in the vectors and other aspects of the dynamics of filarial transmission: the need for vector control against Anopheles-transmitted filariasis","volume":"96(Suppl 2)","author":"Pichon","year":"2002","journal-title":"Ann Trop Med Parasitol"},{"key":"2021091515523890900_CIT0035","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S1471-4922(01)02221-8","article-title":"The PacELF programme: will mass drug administration be enough?","volume":"18","author":"Burkot","year":"2002","journal-title":"Trends Parasitol"},{"key":"2021091515523890900_CIT0036","first-page":"34","article-title":"Control of scabies, skin sores and haematuria in children in the Solomon Islands: another role for ivermectin","volume":"83","author":"Lawrence","year":"2005","journal-title":"Bull World Health Organ"},{"key":"2021091515523890900_CIT0037","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1056\/NEJMoa1500987","article-title":"Mass drug administration for scabies control in a population with endemic disease","volume":"373","author":"Romani","year":"2015","journal-title":"N Engl J Med"},{"key":"2021091515523890900_CIT0038","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1186\/1756-3305-5-299","article-title":"Soil transmitted helminths and scabies in Zanzibar, Tanzania following mass drug administration for lymphatic filariasis\u2014a rapid assessment methodology to assess impact","volume":"5","author":"Mohammed","year":"2012","journal-title":"Parasit Vectors"},{"key":"2021091515523890900_CIT0039","doi-asserted-by":"crossref","first-page":"e0006458","DOI":"10.1371\/journal.pntd.0006458","article-title":"Efficacy and safety of co-administered ivermectin plus albendazole for treating soil-transmitted helminths: a systematic review, meta-analysis and individual patient data analysis","volume":"12","author":"Palmeirim","year":"2018","journal-title":"PLoS Negl Trop Dis"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciab202\/37533071\/ciab202.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/73\/6\/994\/40392529\/ciab202.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/73\/6\/994\/40392529\/ciab202.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,15]],"date-time":"2021-09-15T16:23:05Z","timestamp":1631722985000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/73\/6\/994\/6174432"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,17]]},"references-count":39,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2021,3,17]]},"published-print":{"date-parts":[[2021,9,15]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciab202","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,9,15]]},"published":{"date-parts":[[2021,3,17]]}}}